Fig. 3From: Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutationForest plots of the meta-analysis for the prevalence of TERT promoter mutations in all papillary thyroid carcinomas (PTC), classic PTC (b), follicular variant of PTC (c), and tall cell variant of PTC (d). *Only TERT C228T was examined. TCGA, The Cancer Genome AtlasBack to article page